NASDAQ$PAYS

Paysign Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Reported revenue growth as key performance indicators returned to pre-pandemic normalcy.

Paysign reported positive Q1 2022 results with good revenue growth driven by the rebound of the plasma business and winning new deals and onboarding new plasma centers and pharma clients.

  • Unrestricted cash increased by $1.1 million to $8.5 million due to the improvement of the plasma business.
  • Operating results continued to improve, generating positive cash flow from operations.
  • The company expects total revenue for 2022 to be in the range of $35.25 million to $38.35 million, reflecting growth of 20% to 30%.
  • Adjusted EBITDA is expected to at least double to $4.0 million over 2021.

Headline financials

Total Revenue

$8.22M

Previous: $6.28M+30.9%
EPS (adj)

-$0.01

Previous: -$0.03+66.7%
Capital Expenditures

-$12.8K

Previous: -$125K+89.7%
Free Cash Flow

-$322K

Previous: -$1.75M+81.6%
Net Income

-$309K

Previous: -$1.62M+80.9%
Operating Income

-$322K

Previous: -$1.63M+80.2%
Gross Profit

$5M

Previous: $2.83M+76.5%
Cash & Equivalents

$8.5M

Previous: $65.3M-87.0%
Total Assets

$88.8M

Previous: $77.7M+14.3%
Stock-Based Comp

$570K

Previous: $636K-10.5%

Revenue & EPS history

Paysign · Revenue · Quarterly

$8.22M

Q1 2022+30.9%vs Q1 2021
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Forward guidance

Paysign expects total revenue to be in the range of $35.25 million to $38.35 million, reflecting growth of 20% to 30%. Adjusted EBITDA is expected to at least double to $4.0 million. Full year gross profit margins are expected to be approximately 50.0% to 52.5%. Operating expenses are expected to increase to approximately $20.0 million.

Tailwinds

  • Total revenue to be in the range of $35.25 million to $38.35 million, reflecting growth of 20% to 30%.
  • Plasma making up approximately 90% of total revenue.
  • Adjusted EBITDA is expected to at least double to $4.0 million over 2021’s adjusted EBITDA of $2.0 million.
  • Full year gross profit margins are expected to be approximately 50.0% to 52.5%.
  • Balance sheet remains strong and expects it to continue to expand as an outcome of the operating result improvements

Headwinds

  • Pharma revenue is expected to be relatively flat year over year as the loss of programs and settlement income in 2021 are offset with new pharma copay programs.
  • Operating expenses are expected to increase to approximately $20.0 million as we continue to make investments in people and technology, and experience higher costs in insurance, travel and entertainment and other inflationary pressures.
  • Depreciation and amortization is expected to be between $3.0 million and $3.25 million.
  • Stock-based compensation is expected to be approximately $2.0 million.
  • The company continues to be affected by COVID-19-related labor shortages.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+16.2%

Avg return

Earnings day

+4.1%

Avg return

5 days after

+7.8%

Avg return

30 days after

44%

27 / 61 earnings

Positive

+900.0%

Q3 2011

Best reaction

-29.6%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+37.3%-4.3%
Q1 2026-12.6%-12.0%+4.8%
Q3 2025+0.2%-8.8%+0.4%
Q2 2025+13.0%+4.2%+0.6%
Q1 2025+3.0%+22.9%+81.9%
Q4 2024-8.5%-14.5%-8.1%
Q3 2024+10.9%+8.7%-7.9%
Q2 2024-6.7%-14.4%-9.2%
Q1 2024-0.4%+5.4%-7.6%
Q4 2023+20.5%+10.2%+31.9%
Q3 2023+18.1%+21.6%+18.1%
Q2 2023+6.4%+8.6%+16.0%
Q1 2023-1.8%-4.5%-20.7%
Q4 2022+4.2%+7.6%+0.3%
Q3 2022-10.4%+8.9%+16.5%
Q2 2022+7.4%+15.3%+33.5%
Q1 2022-26.2%-20.2%-2.4%
Q4 2021-6.6%-16.6%-21.4%
Q3 2021-9.0%-14.6%-32.8%
Q2 2021-2.4%+5.6%+16.7%
Q1 2021-11.4%-10.8%+0.0%
Q4 2020+11.7%+5.1%+0.8%
Q3 2020-26.8%-20.6%-7.7%
Q2 2020-18.9%-30.5%-45.3%
Q1 2020-5.5%-13.0%-0.4%
Q4 2019+27.3%+82.9%+102.7%
Q3 2019+13.2%+17.1%+3.9%
Q2 2019+2.5%+6.3%+2.7%
Q1 2019-11.7%-6.7%+18.2%
Q4 2018-1.7%-7.5%-1.0%
Q3 2018-0.5%-1.6%-6.3%
Q2 2018+10.1%+2.7%-2.7%
Q1 2018-0.9%+18.8%+23.1%
Q4 2017+19.0%+20.6%+44.3%
Q3 2017+7.9%+19.3%+15.8%
Q2 2017+2.8%+9.4%+0.0%
Q1 2017-8.7%-6.5%-6.5%
Q4 2016+4.7%+0.0%+0.0%
Q3 2016+34.9%+73.7%+73.7%
Q2 2016+0.0%-5.0%-20.0%
Q1 2016-23.2%
Q4 2015-29.6%
Q3 2015-12.0%
Q2 2015+6.3%
Q1 2015+4.3%
Q4 2014+71.2%
Q2 2014-16.7%
Q1 2014+0.0%
Q4 2013+23.4%
Q3 2013-17.9%
Q2 2013-16.6%
Q4 2012-4.3%
Q1 2013-4.3%
Q3 2012+18.5%
Q2 2012+0.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+900.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010+5.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro